Take­da swoops in and scoops up a cell ther­a­py start­up in buy­out deal, ex­pand­ing on­col­o­gy pipeline

A lit­tle more than 4 years af­ter Take­da stepped in to help bankroll the T cell start­up Gam­maDelta Ther­a­peu­tics with a cool $100 mil­lion in­jec­tion, the glob­al phar­ma play­er is get­ting off the side­lines and buy­ing the biotech for it­self.

Take­da ex­ecs said Wednes­day that they will “ob­tain Gam­maDelta’s al­lo­gene­ic vari­able delta 1 (Vδ1) gam­ma-delta (γδ) T cell ther­a­py plat­forms, which in­cludes both blood-de­rived and tis­sue-de­rived plat­forms, in ad­di­tion to ear­ly-stage cell ther­a­py pro­grams.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER